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The toll-like receptor (TLR) system constitutes a pylogenetically ancient, evolutionary conserved, archetypal pattern recognition
system, which underpins pathogen recognition by and activation of the immune system. Toll-like receptor agonists have long been
used as immunoadjuvants in anti cancer immunotherapy. However, TLRs are increasingly implicated in human disease pathogenesis
and an expanding body of both clinical and experimental evidence suggests that the neoplastic process may subvert TLR signalling
pathways to advance cancer progression. Recent discoveries in the TLR system open a multitude of potential therapeutic avenues.
Extrapolation of such TLR system manipulations to a clinical oncological setting demands care to prevent potentially deleterious
activation of TLR-mediated survival pathways. Thus, the TLR system is a double-edge sword, which needs to be carefully wielded in
the setting of neoplastic disease.
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METHODS
Referenced papers were identified using multiple electronic
searches of the Medline database with the keywords (alone or in
combination): toll-like receptors (TLRs), cancer, TLR ligands, NF-
kB, innate immunity, acquired immunity and immunotherapy.
The search strategy incorporated MESH terms, and results were
evaluated for sensitivity and specificity. Additional articles were
identified from the references of retrieved papers. Papers were
included on the basis of evidence supporting individual points.
BACKGROUND
A total of 13 mammalian toll paralogues (11 of which are expressed
in humans) termed TLR have been described (O’Neill, 2006). Toll-
like receptors expressed on immune system sentinel cells such as
dendritic cells and macrophages sense a range of chemicals
produced by bacteria, viruses, fungi and protozoa. For example
lipid-based predominantly bacterial structures such as myco-
bacterial lipopeptides and lipopolysaccaride are recognised by
TLR2 (in combination with TLR1 or TLR6 as heterodimers) and
TLR4 (as a homodimer), respectively, while viral and/or bacterial
nucleic acids are recognised by TLR3 (stranded RNA (dsRNA)),
TLR7, TLR8 and TLR9 (CpG motifs in DNA). Toll-like receptors
are also extensively expressed on other cell types and may have
endogenous ligands (Cook et al, 2004).
Subsequent TLR-mediated intracellular signalling broadly in-
volves two transduction pathways, which ultimately facilitate
activation of the transcription factor NF-kB, a master switch for
inflammation, regulating the transcription of genes encoding
proteins involved in immunity and inflammation or the MAP
kinases, p38 and Jun amino-terminal kinase (JNK), which
participate in increased transcription and also manipulate the
stability of mRNAs that contain AU repeats (McGettrick and
O’Neill, 2004).
All TLRs activate NF-kB and MAP kinases via a pathway that
involves IRAK-4 and IRAK-1. Fundamental to NF-kB translocation
is IKK kinase (composed of catalytic subunits IKK1 and IKK2 and
regulatory subunit NEMO (NF-kB essential modulator)) activation.
IKK phosporylates the NF-kB inhibitory dimer (consisting of
various p65, p50 subunit combinations). This process is controlled
by the differential recruitment of four adaptor proteins namely
MYD-88, Mal (MyD88 adaptor-like), TRIF (TIR-related adaptor
protein inducing interferon) and TRAM (Trif-related adaptor
molecule) to TLRs. This selective adaptor protein recruitment is
responsible for the different gene expression profiles evident when
individual TLRs are stimulated (O’Neill, 2006).
TLRS AND HUMAN DISEASE PROCESSES
Toll-like receptors are increasingly implicated in disease patho-
genesis (Cook et al, 2004). Population studies of polymorphisms in
genes encoding TLRs or their downstream signalling molecules
in conjunction with limited extrapolation from animal studies
have directly linked these pathways to multiple human disease
processes.
As intuitively expected, many of these polymorphisms are
implicated in infection and sepsis. The initially identified and best
studied D299G polymorphism (an amino acid substitution, from
aspartic acid to glycine at position 299 in the TLR-4 gene) is
associated with an increased frequency of Gram-negative infection
and increased severity of Gram-negative sepsis (Child et al, 2003).
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(Smirnova et al, 2003). The R753Q polymorphism in TLR2 is linked
with reduced response to peptides from Borrelia burgdorferi and
Treponema pallidum, and may predispose to Staphylococcal infection
or tuberculosis (Ogus et al, 2004) while the R677W polymorphism in
TLR2 which impairs activation of NF- B by Mycobacterium leprae
and Mycobacterium tuberculosis apparently enhances susceptibility
to leprosy and tuberculosis (Cook et al, 2004).
Conversely the TLR-4 D299G polymorphism is associated with
decreased risk of carotid artery atherosclerotic stenosis and acute
coronary events (Kiechl et al, 2002).
TLR polymorphisms may underline aspects of asthma and certain
autoimmune conditions. Although the D299G polymorphism has no
effect on the overall incidence of asthma (Raby et al,2 0 0 2 ) ,f o r
asthma specifically associated with house dust mite LPS, people with
the D299G polymorphism had a decreased risk of bronchoreactivity
(Werner et al, 2003) while asthmatic people with this polymorphism
have an increased severity of atopy (Yang et al, 2004).
TLR signalling abnormalities have also been implicated in
immune-deficency conditions. Mutations in gene encoding NEMO
(primarily in exon 10) lead to anhidrotic extodermal dysplasia
(Puel et al, 2004) and a missense mutation involving serine 32 of I
B additionally produces anhidrotic extodermal dysplasia with
immunodeficiency (Courtois et al, 2003).
Overall the expanding body of data has demonstrated important
relationships between TLR signalling pathways and human
disease. Further advances in genetic profiling, intracellular
transduction pathways and effector mechanisms may permit
focused targeting of specific elements of the TLR signalling in
theses disease states.
TLRS AND ANTICANCER IMMUNOTHERAPY
Immunotherapy is an evolving fourth prong to the anticancer
armamentarium and represents a potentially all pervading targeted
nontoxic mechanism to eradicate even micrometastatic disease
(Mocellin et al, 2004). Regrettably harnessing the undisputed
potential of the immune system has proven problematic (Gilboa,
2004).
Extensive research has focused on anticancer vaccination
whereby a tolerant immune system is primed to recognise and
destroy tumour cells. Fundamental to potentiation of immune
responses to tumour-associated antigen (Ag) is the use of
adjuvants, which foster efficient antibody (Ab) production and
killer cell induction (Cheadle and Jackson, 2002).
Since the pioneering work of William Coley, with his
eponymously named Coley’s toxin, attempts to exploit the immune
system using immunopotentiators abound, with microbial pro-
ducts extensively utilised for this purpose (Coley, 1893).
Until recently the underlying mechanism of action of many
immunoadjuvants has remained undefined, possibly impairing
optimal utilisation. Increased understanding of TLR signalling has
allowed elucidation of the molecular basis of such adjuvant activity
with the potential for therapeutic application.
Thus, it is now apparent that the maturation of dendritic cells
(DCs) and cytokine induction underpinning the antineoplastic
activity of Bacillus Calmette-Guerin cel wall skeleton (BCG-CWS) is
mediated by both TLR2 and TLR4 (Tsuji et al, 2000) while the
biological response modifier OK-342 is dependent on the presence
of functioning TLR-4 for its anticancer effect (Okamoto et al,
2003). Double-stranded RNA (dsRNA) activates TLR3 on DCs to
release type 1 IFN that induces tumour cell apoptosis and NK-
mediated tumour cytotoxicity (Whitmore et al, 2004) (Figure 1).
Oligodeoxynucleotides (ODN) with unmethylated deoxycytidyl-
deoxyguanosine (CpG) dinucleotides (CpG ODN) mimic the
immunostimulatory activity of bacterial DNA recognised by the
Toll-like receptor 9 (TLR9) and are potent adjuvants utilised in
cancer therapy (Jahrsdorfer et al, 2005). Imiquimod is a TLR-7
agonist extensively used in the treatment of basal cell carcinoma
(Urosevic et al, 2005).
Recent studies suggest that adjuvants may evoke different
immune responses by targeting distinct TLRs and their intra-
cellular adaptors. Toll-like receptors appear to segregate into
functional subgroups, based on their abilities to modulate
particular types of innate and adaptive immune responses. Toll-
like receptor-7, -8 and -9 induce IFN-a, promote efficient cross-
presentation, cytotoxic T-lymphocyte activation and polarised Th1
responses (Hopkins and Sriskandan, 2005). Signalling via TLRs-3
and -5 also yield a Th1 response and weaker cytotoxic T-cell
reaction while signalling through TLR-4 generates a response with
an atypical Th1 bias (Agrawal et al, 2003). In contrast, many TLR-2
ligands appear to show a Th2 bias (Agrawal et al, 2003). Certain
immune responses can prove beneficial, while others, deleterious
in the neoplastic setting. Thus, it may be possible to engineer the
most appropriate, antitumour immune response by selecting
certain TLR ligands individually, as a cocktail or in conjunction
with other modalities (Koski and Czerniecki, 2005). Moreover, in
addition to selecting a desired immune response it may also be
feasible to break the stranglehold of clone specific immuno-
suppressive regulatory T-cells (T-regs) extensively implicated in
deleterious immune suppression in through explicit targeting of
TLR-8 (Peng et al, 2005).
Furthermore recent studies demonstrated that certain tlr
agonists can directly promote tumour cell death. Salaun et al
showed that synthetic (double stranded) dsRNA induces apoptosis
of human breast cancer cells in a TLR3-dependent manner, which
involves the molecular adaptor Toll/IL-1R domain-containing
adapter inducing IFN-beta and type I IFN autocrine signaling
(Salaun et al), (Figure 1).
TLRS AND CANCER PATHOGENESIS
Analogous to other disease processes direct clinical data indicating
a role for TLRs in cancer progression is scant. Zheng et al (2004)
Appendix:
TLR
Monocytes
T cells
NK cells
Cytotoxic T cells
Macrophages
Tumour cells Necrotic/apoptotic
tumour cells
APC
Activated APC
CD 80
CD 86
MHC II
TLR
TLR-3
agonist
Figure 1 TLR agonists can activate APC, macrophages and cytotoxic T
cells potentially leading to tumour destruction. TLR agonists can also
directly promote tumour cell apoptosis. (TLR-4;Toll-like receptor 4, APC;
antigen presenting cells, MHC; major histocompatability complex).
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and a TLR-4 sequence variant (11381G/C). The variant frequency
was markedly higher in prostate cancer patients compared to
controls and was higher again in early onset cases. Compared to
men with the wild-type genotype, the sequence variant conferred
an overall increased risk of 26% for prostate cancer. This group
also demonstrated a statistically significant relationship between
high risk TLR-4, 6 and 10 haplotype-tagging SNPs (htSNPs) and
prostate cancer in the same population suggestive of a founder
prostate cancer risk variant on this haplotype background
(Sun et al, 2005).
An escalating mass of experimental evidence suggests that the
neoplastic process may sabotage TLR signalling pathways to
advance cancer progression. Contemporary in vivo genetic studies
highlight a more fundamental and direct role for epithelial cell
TLRs and NF-kB in tumour development. Multiple chronic
inflammatory diseases have been associated with cancer develop-
ment including inflammatory bowel disease, hepatitis and chronic
Helicobacter pylori infection predisposing to colorectal, hepato-
cellular and gastric cancer respectively. The published literature
overwhelmingly supports a scenario in which inflammation
promotes (rather than initiates) carcinogenesis in a noncell-
autonomous fashion (Coussens and Werb, 2002). Current doctrine
holds that at sites of inflammation, cytokines, chemokines and
matrix degrading enzymes are released in a persistent unregulated
manner predominantly by cells of the innate immune system
serving to enhance angiogenesis, invasiveness and promote
survival of pre-malignant and neoplastic cells. However, Rakoff-
Nahoum et al (2004) demonstrated that TLR-2, TLR-4 and
MyD88.deficient mice had an unexpectedly increased susceptibility
to dextran sulfate sodium (DSS) colon injury. In this model
commensal bacteria activate TLRs, and the resulting TLR activity
provides protection from colitis-induced damage. Recognition of
bacterial products occurs by TLRs expressed on enterocytes,
residing in an intact epithelial sheet and such activated TLRs then
mediate a cell-autonomous NF-kB dependent cell survival
response. Greten et al (2004) chemically induced colon carcinomas
in mice that do not express IKK2 in their intestinal epithelial cells.
They showed that IKK2-knockout (KO) in intestinal epithelial cells
led to a decrease in tumour incidence (but not tumour size) which
was associated with enhanced epithelial cell apoptosis. Conversely
when IKK2 was specifically deleted in myeloid cells, the chemically
induced colon carcinomas were reduced in size leading the authors
to conclude that, in enterocytes, IKK2 contribute to tumour
promotion by suppressing apoptosis, whereas IKK2 KO in myeloid
cells leads to downregulation of proinflammatory, tumour-
promoting mediators.
Contemporary studies have established a decisive role for
bacterial endotoxin or lipopolysaccaride (LPS) the prototypical
TLR-4 ligand in the increasingly recognised phenomenon of
surgery induced accelerated tumour growth. Following laparotomy
and air laparoscopy, LPS contaminates the peritoneal cavity and
enters the systemic circulation due to perioperative bacterial gut
translocation. In a murine metastatic breast carcinoma model,
mice undergoing laparotomy or air laparoscopy had increased
serum levels of LPS and metastatic tumour burden compared to
those in the CO2 laparoscopy group (which was not contaminated
with endotoxin), a result replicated by intraperitoneal LPS
injection (Pidgeon et al, 1999; Harmey et al, 2002). Luo et al used
TLR-4 deficient CT-26 murine colorectal cancer cells in their study
and suggested that the tumour promoting effect of LPS is
subservient to inflammatory cytokines produced primarily by the
innate immune system, as the LPS-induced enhanced tumour
burden was TNF-a dependent and abolished with super-repressor-
mediated NF-kB inhibition. Moreover the effect was abolished in
TLR-4 deficient mice highlighting the importance of TLRs as
necessary initiators of this phenomenon (Luo et al, 2004). While
this association between LPS and accelerated perioperative tumour
growth may be a manifestation circuitous immunologically
mediated singularity, a direct TLR-4 dependent effect on cancer
cells may also be involved. Huang et al have shown the presence of
TLRs on most cancer cell types (Huang et al, 2005). Andrews et al
(2001) and Wang et al (2003) demonstrated that LPS may also
promote tumour progression by acting directly on cancer cells
resulting in an NF-kB mediated beta 1 integrin dependent
increased in vitro tumour cell endothelial cell adhesion, tumour
cell extracellular matrix adhesion and tumour cell extracellular
matrix invasion. (Figure 2). H. pylori acting via TLR2/TLR9 on
gastric epithelial cells activated both the PI-PLCgamma/PKCalpha/
c-Src/IKKalpha/beta and the NIK/IKKalpha/beta cascade resulting
in increased expression of COX-2 which could potentially
contribute to the gastric cancer progression (Chang et al, 2004).
Furthermore the TLR-signalling pathway may be manipulated
by tumour cells in a manner analogous to the mouse mammary
tumour retro virus which subverts the innate immune system
through the TLR-4 dependent production of the immune
suppressive cytokine IL-10 (Jude et al, 2003). del Fresno et al
(2005) using an in vitro system, indicated that tumour cells
deactivate human monocytes through the release of hyaluronan
which upregulated monocyte IRAK-m in a CD 44 and TLR-4
dependent manner. This tumour-mediated exploitation of TLR
signalling may also apply to the adaptive immune system. Huang
et al established that activation of TLR-4 signalling in tumour cells
by lipopolysaccharide induced the synthesis of various soluble
factors and proteins including interleukin-6, inducible nitric oxide
synthase, interleukin-12, B7-H1, and B7-H2 resulting in resistance
of tumour cells to cytotoxic T-lymphocyte (CTL) attack. Blockade
of the TLR-4 pathway reversed tumour-mediated suppression of
T-cell proliferation and natural killer cell activity in vitro, and in
vivo, delaying tumour growth and prolonging survival of tumour-
bearing mice (Huang et al, 2005). Taken together such findings
indicate that tumour cell TLR signalling may be subverted by the
neoplastic process resulting in a cascade leading to enhanced
tumour cell invasion and immune surveillance evasion.
Allied to this is a reputed role for TLRs in the immune response
to self-molecules that have in some way been altered from their
native state or accumulated in nonphysiologic sites or quantities.
Several putative endogenous ligands have been reported including
hsp60, hsp70, gp96, fibrinogen, surfactant protein A, the extra
domain A of fibronectin, HMGB-1, Heparan sulphate, hyaluronan
TLR agonists
Tumour cells
↑ Tumour cell
proliferation 
u-PA  
 integrin 1
u-PAR 
B-71
B-72
↑ Tumour cell–ECM adhesion
↑ Tumour cell–ECM invasion
TLR
Figure 2 TLR agonists can directly promote enhanced tumour cell
adhesion and invasion through the upregulation of proteases such as the
urokinase plasminogen activator system and beta integrin 1, ultimately
facilitating tumour progression (TLR-4;Toll-like receptor 4, u-PA: urokinase
plasminogen activator, pro-u-PA: pro-urokinase plasminogen activator
(zymogen), u-PAR; urokinase plasminogen activator receptor, MMP; matrix
metalloprotease, pro-MMP, promatrix metalloprotease (zymogen)).
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compounds, in pathologies as diverse as pancreatitis and
haemorrhage-induced lung injury (Johnson et al, 2004). A
provocative hypothesis proposed by Zeh et al states that cancer
is a disorder of cell death rather than cell growth propelled by the
release of necrotic products such as HMGB-1 to which tumour
cells become ‘addicted’. Such products could possibly act through
TLRs expressed by cancer cells. Therefore, other endogenous
ligands which are increased in the tumour environment could also
modify both the local inflammatory response at the tumour site
and the rate of tumour-cell growth (Zeh and Lotze, 2005).
Although ligands that drive TLR-mediated tumour cell immune
suppression have yet to be identified, endogenous compounds
could well be involved (Huang et al, 2005). Johnson et al have
recently demonstrated that signalling through TLR4 function is
apparently strongly inhibited by intact extracellular matrix (ECM)
and this inhibition is abrogated and endogenous agonist(s)
liberated when the matrix is degraded (Brunn et al, 2005). Thus,
escape from ECM mediated inhibition, due to ECM breakdown
caused by proteases released in the course of infection or injury,
may be the critical first event by which TLRs initiate immune
responses. By extrapolation this pathway could also be utilised by
cancer cells to institute a self propagating autonomous autocrine
loop. Thus, protease secretion by cancer cells leads not only to
extracellular matrix degradation with enhanced tumour cell
invasion but also release of tumour cell TLR apparatus from
matrix constrains and liberation of putative TLR ligand. This
culminates in TLR stimulation, corruption of the intracellular
signalling pathways and the production of tumour promoting
compounds including proteases. Such proteases promote tumour
progression and further degrade the extracellular matrix perpe-
tually maintaining this proposed autocrine loop ad infinitium
(see Figure 3). Speculation regarding any possible association
of endogenous TLR ligands in tumour progression must, however,
be tempered by concerns regarding possible confounding
contaminating microbial pathogen associated molecular patterns
(PAMPs) such as LPS (Tsan and Gao, 2004; Geisler et al, 2005) and
also a putative direct cytotoxic effect of certain TLR agonists on
cancer cells. Collectively these studies suggest that certain PAMPs
and endogenous compounds acting directly through TLRs on
transformed cells can trigger the NF-kB survival pathway serving
to upregulate a plethora of antiapoptotic, proinvasive and immune
evasive mechanisms. Subversion of the TLR signalling pathway
by neoplasms constitutes a new paradigm in cancer progression,
one open to potentially beneficial manipulation with careful
intervention.
FUTURE DIRECTIONS
Recent advances in the field of TLR signalling have opened a
multitude of oncological therapeutic opportunities. Given the
apparent appropriation of certain immune responses by TLR
subgroups it may be possible to generate a desired immune
response in cancer patients based on adjuvant TLR activity. The
counterproductive or even deleterious stimulation of TLRs on
tumour cells could be avoid by profiling the TLR status on tumour
cells and selecting adjuvants which will be recognised by immune
cell but not cancer cell TLRs thereby preventing activation of the
prosurvival TLR signalling pathways in cancer cells. The subver-
sion of the TLR system by the neoplastic process is another valid
interventional target. However, targeting of TLRs may potentially
disrupt beneficial host immunity and homeostatic functions,
provoke damaging autoimmune phenomena and interfer with
concurrent therapeutic regimens. Furthermore putative endogen-
ous TLR ligands need to be identified, the precise details of
ligand–receptor interactions and their contribution to cancer
pathogenesis, clarified.
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Figure 3 A putative self perpetuating, neoplastic paracrine loop, whereby protease degraded extracellular matrix components (ECM) release the tumour
cell TLR signalling apparatus from inhibition and stimulate this pathway, culminating in enhanced protease production and hence ECM breakdown. (TLR-
4;Toll-like receptor 4, u-PA: urokinase plasminogen activator, pro-u-PA: pro-urokinase plasminogen activator (zymogen), u-PAR; urokinase plasminogen activator
receptor, MMP; matrix metalloprotease, pro-MMP, promatrix metalloprotease (zymogen)).
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The TLR system is a keystone of immunoadjuvant therapy. With
further understanding of TLR function, signalling and effector
mechanisms, manipulation of this pathway holds great potential in
cancer treatment. However, such strategies are not without risk.
The TLR system of immune and cancer cells alike, is actively
subverted by the neoplastic process to advance disease propoga-
tion and this system coupled with putative endogenous ligands
may actually comprise a novel paracrine self propagating feedback
loop. Hence, the TLR system constitutes a double edge sword that
needs to be carefully wielded in the setting of neoplastic disease.
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